Hem › Multipelt myelom › Rhode Island
Kliniska studier för Multipelt myelom i Rhode Island
6 studier för Multipelt myelom söker deltagare vid platser i Rhode Island.
Städer i Rhode Island
Officiell studietext (engelska)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Rhode Island Hospital, Providence
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05552222MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Rodhe Island Hospital, Providence
- The Miriam Hospital, Providence
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 aug. 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 19 aug. 2026 · NCT04566328Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RekryterarFas 3
Alla åldrar · Alla kön · Uppdaterad 10 juni 2026 · NCT05561387A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Providence
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 22 apr. 2026 · NCT06679101IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Rhode Island Hospital, Providence
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 3 juni 2025 · NCT06119685Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.